JP2023535444A5 - - Google Patents
Info
- Publication number
- JP2023535444A5 JP2023535444A5 JP2023504622A JP2023504622A JP2023535444A5 JP 2023535444 A5 JP2023535444 A5 JP 2023535444A5 JP 2023504622 A JP2023504622 A JP 2023504622A JP 2023504622 A JP2023504622 A JP 2023504622A JP 2023535444 A5 JP2023535444 A5 JP 2023535444A5
- Authority
- JP
- Japan
- Prior art keywords
- complex according
- antibody
- oligonucleotide
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055768P | 2020-07-23 | 2020-07-23 | |
| US63/055,768 | 2020-07-23 | ||
| US202063061839P | 2020-08-06 | 2020-08-06 | |
| US63/061,839 | 2020-08-06 | ||
| US202163143828P | 2021-01-30 | 2021-01-30 | |
| US63/143,828 | 2021-01-30 | ||
| US202163181456P | 2021-04-29 | 2021-04-29 | |
| US63/181,456 | 2021-04-29 | ||
| PCT/US2021/040987 WO2022020106A1 (en) | 2020-07-23 | 2021-07-09 | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535444A JP2023535444A (ja) | 2023-08-17 |
| JP2023535444A5 true JP2023535444A5 (https=) | 2024-07-11 |
| JP7851294B2 JP7851294B2 (ja) | 2026-04-24 |
Family
ID=79729849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504622A Active JP7851294B2 (ja) | 2020-07-23 | 2021-07-09 | 顔面肩甲上腕型筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230272065A1 (https=) |
| EP (1) | EP4185314A4 (https=) |
| JP (1) | JP7851294B2 (https=) |
| KR (1) | KR20230046297A (https=) |
| CN (1) | CN116348139A (https=) |
| AU (1) | AU2021313057A1 (https=) |
| BR (1) | BR112023001003A2 (https=) |
| CA (1) | CA3186746A1 (https=) |
| IL (1) | IL299666A (https=) |
| MX (1) | MX2023000961A (https=) |
| WO (1) | WO2022020106A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| KR20230023612A (ko) | 2020-04-02 | 2023-02-17 | 마이레큘, 인크. | 조작된 올리고뉴클레오티드를 사용한 표적화된 억제 |
| CN116194470B (zh) * | 2020-07-23 | 2025-10-03 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| EP4185320A4 (en) * | 2020-07-23 | 2025-10-08 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) * | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| EP4551230A2 (en) * | 2022-07-06 | 2025-05-14 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2025522877A (ja) * | 2022-07-06 | 2025-07-17 | ダイン セラピューティクス，インコーポレーテッド | Ｃｎｓ標的化複合体およびその使用 |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025255283A1 (en) * | 2024-06-07 | 2025-12-11 | Dyne Therapeutics, Inc. | Dosing of muscle targeting complexes for treating facioscapulohumeral muscular dystrophy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10538763B2 (en) * | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| GB201512365D0 (en) * | 2015-07-15 | 2015-08-19 | King S College London | Novel therapy |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| DK3473270T5 (da) | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| MX2019008199A (es) * | 2017-01-06 | 2019-11-25 | Avidity Biosciences Llc | Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon. |
| TWI869346B (zh) * | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| SG11202100928QA (en) * | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| WO2020028842A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| AU2019314538B2 (en) * | 2018-08-02 | 2025-03-13 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2020028836A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
| IL312067B2 (en) * | 2018-12-21 | 2025-08-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and uses thereof |
-
2021
- 2021-07-09 KR KR1020237005852A patent/KR20230046297A/ko active Pending
- 2021-07-09 MX MX2023000961A patent/MX2023000961A/es unknown
- 2021-07-09 IL IL299666A patent/IL299666A/en unknown
- 2021-07-09 BR BR112023001003A patent/BR112023001003A2/pt unknown
- 2021-07-09 US US18/017,173 patent/US20230272065A1/en active Pending
- 2021-07-09 CN CN202180065042.1A patent/CN116348139A/zh active Pending
- 2021-07-09 JP JP2023504622A patent/JP7851294B2/ja active Active
- 2021-07-09 WO PCT/US2021/040987 patent/WO2022020106A1/en not_active Ceased
- 2021-07-09 EP EP21846007.9A patent/EP4185314A4/en active Pending
- 2021-07-09 AU AU2021313057A patent/AU2021313057A1/en active Pending
- 2021-07-09 CA CA3186746A patent/CA3186746A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023535444A5 (https=) | ||
| JP2021533200A5 (https=) | ||
| JP2021532832A5 (https=) | ||
| JP2021533197A5 (https=) | ||
| JP2024525614A5 (https=) | ||
| JP2024546436A5 (https=) | ||
| JP2023535078A5 (https=) | ||
| JP2021533199A5 (https=) | ||
| JP2023512442A5 (https=) | ||
| JP2024501872A5 (https=) | ||
| JP2023535074A5 (https=) | ||
| US9506064B2 (en) | Cell-type specific aptamer-siRNA delivery system for HIV-1 therapy | |
| US11384356B2 (en) | Composition and method for oligonucleotide delivery | |
| JP2023510351A5 (https=) | ||
| KR101605932B1 (ko) | Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물 | |
| Wullner et al. | Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2 | |
| EP2121929B1 (en) | Targeted delivery of sirna | |
| KR20230044242A (ko) | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 | |
| JP2023512441A5 (https=) | ||
| JP2008527993A (ja) | 特異性及び送達の改善のためのｓｉＲＮＡ分子、ｓｈＲＮＡ分子又はアンチセンス分子及び機能的実体を含む複合体 | |
| CA3209418A1 (en) | Compositions and methods for modulating pnpla3 expression | |
| US20250205352A1 (en) | COMPOSITIONS AND METHODS FOR MODULATING NaV1.8 | |
| JP7216381B2 (ja) | Ｒｎａ作用抑制剤及びその利用 | |
| AU2019213316B2 (en) | Organic compositions to treat HSF1-related diseases | |
| Prater | Antisense oligonucleotides directed to the HIV-1 Rev Response Element: Effects of nucleotide modification on oligo binding affinity, nuclease stability, and cellular uptake |